Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-12 axicabtagene ciloleucel first-line study in high-risk large B-cell lymphoma
2019-002291-13Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Sep 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma, sponsored by Kite Pharma. Primary endpoint: Complete Response (CR) rate. Started Sep 2019; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on 2019-002291-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002291-13.